Lisocabtagene Maraleucel (Breyanzi)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses lisocabtagene maraleucel (liso-cel; Breyanzi), 60 × 106 to 120 × 106 CAR-positive viable T cells, presented as a cell suspension in patient-specific single-dose vials, for IV infusion (1-time infusion, non–weight-based dose).
• Indication: For the treatment of adult patients with DLBCL NOS, PMBCL, HGBCL, and DLBCL arising from follicular lymphoma, who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy, and who are candidates for autologous HSCT.